Eugene A. Bauer Sells 7,500 Shares of Dermira, Inc. (DERM) Stock

Dermira, Inc. (NASDAQ:DERM) insider Eugene A. Bauer sold 7,500 shares of the stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total value of $225,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.04). The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%.

TRADEMARK VIOLATION WARNING: “Eugene A. Bauer Sells 7,500 Shares of Dermira, Inc. (DERM) Stock” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2957999/eugene-a-bauer-sells-7500-shares-of-dermira-inc-derm-stock.html.

A number of analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $45.00 price objective on shares of Dermira in a research report on Tuesday, September 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price objective on shares of Dermira in a research report on Sunday, September 17th. Mizuho reaffirmed a “buy” rating and set a $43.00 price objective (up from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, BidaskClub raised Dermira from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 16th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $44.40.

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of Dermira during the first quarter worth approximately $1,023,000. Vanguard Group Inc. lifted its position in Dermira by 20.7% in the first quarter. Vanguard Group Inc. now owns 1,272,700 shares of the biopharmaceutical company’s stock worth $43,412,000 after purchasing an additional 217,943 shares during the period. Rhumbline Advisers lifted its position in Dermira by 57.1% in the second quarter. Rhumbline Advisers now owns 43,781 shares of the biopharmaceutical company’s stock worth $1,276,000 after purchasing an additional 15,905 shares during the period. Platinum Investment Management Ltd. lifted its position in Dermira by 28.8% in the second quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock worth $1,681,000 after purchasing an additional 12,900 shares during the period. Finally, Nicholas Investment Partners LP lifted its position in Dermira by 19.3% in the second quarter. Nicholas Investment Partners LP now owns 127,004 shares of the biopharmaceutical company’s stock worth $3,704,000 after purchasing an additional 20,587 shares during the period. Institutional investors and hedge funds own 97.56% of the company’s stock.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.